Drugs help AIDS patients
With 42 approved medicines now available for AIDS and its opportunistic infections and 122 others in development, scientists are becoming increasingly optimistic about turning the disease into a manageable condition, according to an official at the Pharmaceutical Research and Manufacturers of America, Washington.
With 42 approved medicines now available for AIDS and its opportunistic infections and 122 others in development, scientists are becoming increasingly optimistic about turning the disease into a manageable condition, according to an official at the Pharmaceutical Research and Manufacturers of America, Washington.
"With new protease inhibitor drugs, HIV content in blood has been lowered in some patients by up to 99%," said John Siegfried, M.D., deputy vice president for regulatory and scientific affairs. "As President Clinton recently noted, new medicines have doubled the life expectancy of people with HIV over the last four years."
Siegfried emphasized that "the variety and usefulness of today's new AIDS medicines are improving. In addition to protease inhibitors, scientists are developing new immunomodulator drugs to strengthen the body's immune system. Ten immunomodulators are being tested in both healthy volunteers and patient volunteers."
Scientists are also testing 13 new vaccines that could either prevent or treat HIV infection, as well as 37 pharmaceutical products that fight opportunistic infections and AIDS-related cancers. More than forty antiviral medicines and four gene therapies are also in development. PR
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
